Charting HIV's remarkable voyage through the cell: Bas therapy

Nature Medicine 8, 673-680 DOI: 10.1038/nm0702-673

Citation Report

#	Article	IF	CITATIONS
1	An intracellular block to primate lentivirus replication. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11549-11551.	3.3	45
2	Unchain my heart, baby let me go—the entry and intracellular transport of HIV. Journal of Cell Biology, 2002, 159, 393-395.	2.3	37
3	HIV/host interactions: new lessons from the Red Queen's country. Aids, 2002, 16, S25-S31.	1.0	6
4	Mechanisms of enveloped RNA virus budding. Trends in Cell Biology, 2002, 12, 569-579.	3.6	247
5	The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets. Expert Review of Anti-Infective Therapy, 2003, 1, 97-128.	2.0	48
10	Biomimetic Total Synthesis of Litseaverticillols A, C, D, F, and C: Singlet-Oxygen-Initiated Cascades. Angewandte Chemie - International Edition, 2003, 42, 5465-5468.	7.2	60
11	HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature, 2003, 424, 213-219.	13.7	216
12	HIV and AIDS: 20 years of science. Nature Medicine, 2003, 9, 839-843.	15.2	193
13	Hide, shield and strike back: how HIV-infected cells avoid immune eradication. Nature Reviews Immunology, 2003, 3, 97-107.	10.6	140
14	Analysis of nuclear targeting activities of transport signals in the human immunodeficiency virus Rev protein. Experimental Cell Research, 2003, 291, 484-501.	1.2	12
15	Vpu from HIV-1 on an atomic scale: experiments and computer simulations. FEBS Letters, 2003, 552, 39-46.	1.3	29
16	HIV Disease. Dental Clinics of North America, 2003, 47, 467-492.	0.8	17
17	Molecular biology of the human immunodeficiency virus: current and future targets for intervention. Seminars in Pediatric Infectious Diseases, 2003, 14, 258-268.	1.7	6
18	Barrier-to-Autointegration Factor BAF Binds p55 Gagand Matrix and Is a Host Component of Human ImmunodeficiencyVirus Type 1Virions. Journal of Virology, 2003, 77, 13084-13092.	1.5	47
19	Cholesterol Depletion of Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus with β-Cyclodextrin Inactivates and Permeabilizes the Virions: Evidence for Virion-Associated Lipid Rafts. Journal of Virology, 2003, 77, 8237-8248.	1.5	193
20	Nuclear Protein Phosphatase-1 Regulates HIV-1 Transcription. Journal of Biological Chemistry, 2003, 278, 32189-32194.	1.6	49
21	Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. Journal of Leukocyte Biology, 2003, 74, 736-749.	1.5	125
22	Human Immunodeficiency Virus Hematology. Hematology American Society of Hematology Education Program, 2003, 2003, 294-313.	0.9	55

#	Article	IF	CITATIONS
23	Practical applications of viral fitness in clinical practice. Current Opinion in Infectious Diseases, 2003, 16, 11-18.	1.3	30
24	Anti-HIV-1 activity of leflunomide. Aids, 2003, 17, 1613-1620.	1.0	37
25	Glycoprotein gp120-mediated astrocytic dysfunction. Advances in Molecular and Cell Biology, 2003, 31, 921-949.	0.1	0
26	Handling infectious agents in the ART laboratory. , 2004, , 332-352.		0
27	Proteomic Studies of Human Lymphocytes: New Insights into HIV Lymphocyte Infection?. , 2004, , 245-262.		2
28	Chemokines and their Receptors as Therapeutic Targets: The Role of the SDF-1 / CXCR4 Axis. Current Pharmaceutical Design, 2004, 10, 1245-1259.	0.9	104
29	Interactions of Processed Nef (58-206) with Virion Proteins of HIV Type 1. AIDS Research and Human Retroviruses, 2004, 20, 399-407.	0.5	6
30	Migration ofAntigen-Specific T Cells Away from CXCR4-Binding Human ImmunodeficiencyVirus Type 1gp120. Journal of Virology, 2004, 78, 5184-5193.	1.5	29
31	Patterns of ethnic diversity among the genes that influence AIDS. Human Molecular Genetics, 2004, 13, 9R-19.	1.4	46
32	Assessment of the Role of the Central DNA Flap in Human Immunodeficiency Virus Type 1 Replication by Using a Single-Cycle Replication System. Journal of Virology, 2004, 78, 3170-3177.	1.5	49
33	Secretory Leukocyte Protease Inhibitor Binds to Annexin II, a Cofactor for Macrophage HIV-1 Infection. Journal of Experimental Medicine, 2004, 200, 1337-1346.	4.2	193
34	Identification of Staufen in the Human Immunodeficiency Virus Type 1 Gag Ribonucleoprotein Complex and a Role in Generating Infectious Viral Particles. Molecular and Cellular Biology, 2004, 24, 2637-2648.	1.1	111
35	Entry and Transcription as Key Determinants of Differences in CD4 T-Cell Permissiveness to Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2004, 78, 10747-10754.	1.5	46
36	Nef Binds p6* in GagPol during Replication of Human Immunodeficiency Virus Type 1. Journal of Virology, 2004, 78, 5311-5323.	1.5	29
37	Host Factors That Affect Ty3 Retrotransposition in Saccharomyces cerevisiae. Genetics, 2004, 168, 1159-1176.	1.2	47
38	Conservation of a Stepwise, Energy-Sensitive Pathway Involving HP68 for Assembly of Primate Lentivirus Capsids in Cells. Journal of Virology, 2004, 78, 1645-1656.	1.5	57
39	Human Immunodeficiency Virus (HIV) Type 1 Vpu Induces the Expression of CD40 in Endothelial Cells and Regulates HIV-Induced Adhesion of B-Lymphoma Cells. Journal of Virology, 2004, 78, 4408-4420.	1.5	17
40	Binding and Susceptibility to Postentry Restriction Factors in Monkey Cells Are Specified by Distinct Regions of the Human Immunodeficiency Virus Type 1 Capsid. Journal of Virology, 2004, 78, 5423-5437.	1.5	116

#	Article	IF	CITATIONS
41	How resting T cells deMURR HIV infection. Nature Immunology, 2004, 5, 18-19.	7.0	14
42	The brightening future of HIV therapeutics. Nature Immunology, 2004, 5, 867-871.	7.0	33
43	HIV evolution: CTL escape mutation and reversion after transmission. Nature Medicine, 2004, 10, 282-289.	15.2	769
44	BAF: roles in chromatin, nuclear structure and retrovirus integration. Trends in Cell Biology, 2004, 14, 261-266.	3.6	154
45	To exploit the exploitation of actin by HIV?. Drug Discovery Today, 2004, 9, 2-4.	3.2	2
46	HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion. Virology, 2004, 328, 36-44.	1.1	59
47	Expression of HIV-1 integrase in CEM cells inhibits HIV-1 replication. Journal of Gene Medicine, 2004, 6, 268-277.	1.4	1
48	Role of Nup98 in nuclear entry of human immunodeficiency virus type 1ÂcDNA. Microbes and Infection, 2004, 6, 715-724.	1.0	55
50	Role of Nup98 in nuclear entry of human immunodeficiency virus type 1BcDNA. Microbes and Infection, 2004, 6, 715-715.	1.0	7
51	HIV-1 encoded candidate micro-RNAs and their cellular targets. Retrovirology, 2004, 1, 43.	0.9	181
52	Nuclear organization and the control of HIV-1 transcription. Gene, 2004, 326, 1-11.	1.0	44
53	Control of HIV-1 replication by RNA interference. Virus Research, 2004, 102, 53-58.	1.1	71
54	HIV–host interactions: vital to the virus and key to its inhibition. Current Opinion in Microbiology, 2004, 7, 407-411.	2.3	22
55	HIV–host interactions: vital to the virus and key to its inhibition. Current Opinion in Microbiology, 2004, 7, 555-559.	2.3	33
56	Mutual Functional Destruction of HIV-1 Vpu and Host TASK-1 Channel. Molecular Cell, 2004, 14, 259-267.	4.5	134
57	New Therapies Targeting Chemokine Receptors: Can Changing the Way Cells Traffic be Used to Treat Human Disease?. Current Topics in Membranes, 2005, , 331-365.	0.5	1
58	Adaptation, co-evolution, and human susceptibility to HIV-1 infection. Infection, Genetics and Evolution, 2005, 5, 327-334.	1.0	15
59	Transcellular protein transduction using the Tat protein of HIV-1. Advanced Drug Delivery Reviews, 2005, 57, 597-608.	6.6	102

#	Article	IF	Citations
60	Perils at mucosal front lines for HIV and SIV and their hosts. Nature Reviews Immunology, 2005, 5, 783-792.	10.6	377
61	The Nef Protein of Human Immunodeficiency Virus Establishes Superinfection Immunity by a Dual Strategy to Downregulate Cell-Surface CCR5 and CD4. Current Biology, 2005, 15, 714-723.	1.8	400
62	Role of HIV-2 envelope in Lv2-mediated restriction. Virology, 2005, 332, 347-358.	1.1	32
63	T Cell Suicide Gene Therapy to Aid Haematopoietic Stem Cell Transplantation. Current Gene Therapy, 2005, 5, 121-132.	0.9	12
64	Highly Active Antiretroviral Therapy: Current State of the Art, New Agents and Their Pharmacological Interactions Useful for Improving Therapeutic Outcome. Current Pharmaceutical Design, 2005, 11, 1805-1843.	0.9	222
65	Potential Effect of HIV Type 1 Antiretroviral and Herpes Simplex Virus Type 2 Antiviral Therapy on Transmission and Acquisition of HIV Type 1 Infection. Journal of Infectious Diseases, 2005, 191, S107-S114.	1.9	78
66	Retroviruses and yeast retrotransposons use overlapping sets of host genes. Genome Research, 2005, 15, 641-654.	2.4	85
67	Solution Structure of the Human Immunodeficiency Virus Type 1 p6 Protein*. Journal of Biological Chemistry, 2005, 280, 42515-42527.	1.6	55
68	Cocaine and Â-1 receptors modulate HIV infection, chemokine receptors, and the HPA axis in the huPBL-SCID model. Journal of Leukocyte Biology, 2005, 78, 1198-1203.	1.5	75
69	Nuclear Targeting of Protein Phosphatase-1 by HIV-1 Tat Protein. Journal of Biological Chemistry, 2005, 280, 36364-36371.	1.6	55
70	The ubiquitin–proteasome system in HIV replication: potential targets for antiretroviral therapy. Expert Review of Anti-Infective Therapy, 2005, 3, 61-79.	2.0	38
71	Rodent Cells Support Key Functions of the Human Immunodeficiency Virus Type 1 Pathogenicity Factor Nef. Journal of Virology, 2005, 79, 1655-1665.	1.5	44
72	Regulation of Human Immunodeficiency Virus Type 1 Gene Expression by Clade-Specific Tat Proteins. Journal of Virology, 2005, 79, 9180-9191.	1.5	37
73	Heat Shock Protein 40 Is Necessary for Human Immunodeficiency Virus-1 Nef-mediated Enhancement of Viral Gene Expression and Replication. Journal of Biological Chemistry, 2005, 280, 40041-40050.	1.6	67
74	Recombinant Human Immunodeficiency Virus Type 1 Integrase Exhibits a Capacity for Full-Site Integration In Vitro That Is Comparable to That of Purified Preintegration Complexes from Virus-Infected Cells. Journal of Virology, 2005, 79, 8208-8216.	1.5	77
75	Use of a Combined Ex Vivo/In Vivo Population Approach for Screening of Human Genes Involved in the Human Immunodeficiency Virus Type 1 Life Cycle for Variants Influencing Disease Progression. Journal of Virology, 2005, 79, 12674-12680.	1.5	56
76	COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells. Nucleic Acids Research, 2005, 33, 2318-2331.	6.5	98
77	The Role of the Cytoskeleton During Viral Infection. , 2005, 285, 67-108.		132

	CITATION R	EPORT	
#	Article	IF	CITATIONS
78	Anti-HIV activities of organic and aqueous extracts of Sutherlandia frutescens and Lobostemon trigonus. Journal of Ethnopharmacology, 2005, 96, 113-119.	2.0	80
79	Basics of the virology of HIV-1 and its replication. Journal of Clinical Virology, 2005, 34, 233-244.	1.6	109
80	Infectious Agents Transmitted by Transfusion. , 0, , 701-773.		3
81	SNFing HIV transcription. Retrovirology, 2006, 3, 49.	0.9	19
82	Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks. Retrovirology, 2006, 3, 81.	0.9	18
83	Biochemical Indication for Myristoylation-Dependent Conformational Changes in HIV-1 Nef. Biochemistry, 2006, 45, 2339-2349.	1.2	58
85	Host genetics of HIV-1 susceptibility. Future Virology, 2006, 1, 55-70.	0.9	13
86	Diketo Acids Derivatives as Integrase Inhibitors: The War Against the Acquired Immunodeficiency Syndrome. Recent Patents on Anti-infective Drug Discovery, 2006, 1, 255-265.	0.5	2
87	Host polymorphism in steps of the HIV-1 lifecycle after entry and other genetic variants influencing HIV-1 pathogenesis. Current Opinion in HIV and AIDS, 2006, 1, 232-240.	1.5	3
89	HIVâ€1 Persistence, Viral Reservoir, and the Central Nervous System in the HAART Era. Brain Pathology, 2003, 13, 95-103.	2.1	79
90	The inner-nuclear-envelope protein emerin regulates HIV-1 infectivity. Nature, 2006, 441, 641-645.	13.7	95
91	Understanding Human Immunodeficiency Virus Type 1 and Hepatitis C Virus Coinfection. Current HIV Research, 2006, 4, 21-30.	0.2	17
92	Susceptibility to HIV Infection—Disentangling Host Genetics and Host Behavior. Journal of Infectious Diseases, 2006, 193, 4-6.	1.9	12
93	HIV-1 Nef upregulates CCL2/MCP-1 expression in astrocytes in a myristoylation- and calmodulin-dependent manner. Journal of Cell Science, 2006, 119, 4520-4530.	1.2	52
94	Dynamics of Virus-Host Interplay in HIV-1 Replication. Current HIV Research, 2006, 4, 117-130.	0.2	30
95	Inhibition of Early Steps of HIV-1 Replication by SNF5/Ini1. Journal of Biological Chemistry, 2006, 281, 22736-22743.	1.6	42
96	Inhibitors of HIV-1 protease: 10 years after. Expert Opinion on Therapeutic Patents, 2006, 16, 1067-1091.	2.4	20
97	The Nef Protein of Human Immunodeficiency Virus Is a Broad-Spectrum Modulator of Chemokine Receptor Cell Surface Levels That Acts Independently of Classical Motifs for Receptor Endocytosis and GαiSignaling. Molecular Biology of the Cell, 2006, 17, 3578-3590.	0.9	33

#	Article	IF	CITATIONS
98	Interaction between HIV-1 Rev and Integrase Proteins. Journal of Biological Chemistry, 2007, 282, 15743-15753.	1.6	50
99	The transcriptional cycle of HIV-1 in real-time and live cells. Journal of Cell Biology, 2007, 179, 291-304.	2.3	174
100	Requirement for an Intact T-Cell Actin and Tubulin Cytoskeleton for Efficient Assembly and Spread of Human Immunodeficiency Virus Type 1. Journal of Virology, 2007, 81, 5547-5560.	1.5	177
101	The Host Protein Staufen1 Participates in Human Immunodeficiency Virus Type 1 Assembly in Live Cells by Influencing pr55 Gag Multimerization. Journal of Virology, 2007, 81, 6216-6230.	1.5	60
102	Reverse transcription complex: the key player of the early phase of HIV replication. Future Virology, 2007, 2, 49-64.	0.9	8
104	A history of AIDS: Looking back to see ahead. European Journal of Immunology, 2007, 37, S94-S102.	1.6	109
105	HIV drug development: the next 25 years. Nature Reviews Drug Discovery, 2007, 6, 959-966.	21.5	262
106	Modulation of the immunological synapse: a key to HIV-1 pathogenesis?. Nature Reviews Immunology, 2007, 7, 310-317.	10.6	121
107	Application of proteomics technology for analyzing the interactions between host cells and intracellular infectious agents. Proteomics, 2008, 8, 852-873.	1.3	31
108	Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nature Cell Biology, 2008, 10, 211-219.	4.6	666
109	Derivation of infectious HIV-1 molecular clones with LTR mutations: Sensitivity to the CD8+ cell noncytotoxic anti-HIV response. Virology, 2008, 373, 30-38.	1.1	9
110	Lysine methylation of HIV-1 Tat regulates transcriptional activity of the viral LTR. Retrovirology, 2008, 5, 40.	0.9	75
111	The host protein Staufen1 interacts with the Pr55Gagzinc fingers and regulates HIV-1 assembly via its N-terminus. Retrovirology, 2008, 5, 41.	0.9	64
112	The histone chaperone protein Nucleosome Assembly Protein-1 (hNAP-1) binds HIV-1 Tat and promotes viral transcription. Retrovirology, 2008, 5, 8.	0.9	48
113	Selective translational repression of HIV-1 RNA by Sam68DeltaC occurs by altering PABP1 binding to unspliced viral RNA. Retrovirology, 2008, 5, 97.	0.9	14
114	Donor variability in HIV binding to peripheral blood mononuclear cells. Virology Journal, 2008, 5, 95.	1.4	6
115	NeuroAIDS. Molecular Diagnosis and Therapy, 2008, 12, 25-43.	1.6	48
116	Human Immunodeficiency Virus Type 1 Vpu Protein Interacts with CD74 and Modulates Major Histocompatibility Complex Class II Presentation. Journal of Virology, 2008, 82, 893-902.	1.5	48

IF

CITATIONS

117	Immunopharmacology. , 2008, , .		6
118	MULTI-AGENT SIMULATIONS OF THE IMMUNE RESPONSE TO HIV DURING THE ACUTE STAGE OF INFECTION. International Journal of Modern Physics C, 2008, 19, 15-32.	0.8	4
119	Novel Cytotoxic T-Lymphocyte Escape Mutation by a Three-Amino-Acid Insertion in the Human Immunodeficiency Virus Type 1 p6 ^{Pol} and p6 ^{Gag} Late Domain Associated with Drug Resistance. Journal of Virology, 2008, 82, 495-502.	1.5	16
120	Acetylation of Conserved Lysines in the Catalytic Core of Cyclin-Dependent Kinase 9 Inhibits Kinase Activity and Regulates Transcription. Molecular and Cellular Biology, 2008, 28, 2201-2212.	1.1	81
121	The HIV-1 Vif Protein Mediates Degradation of Vpr and Reduces Vpr-Induced Cell Cycle Arrest. DNA and Cell Biology, 2008, 27, 267-277.	0.9	18
122	The Ty1 integrase protein can exploit the classical nuclear protein import machinery for entry into the nucleus. Nucleic Acids Research, 2008, 36, 4317-4326.	6.5	32
123	Identification of Potential Drug Targets Using Genomics and Proteomics: A Systems Approach. Advances in Pharmacology, 2008, 56, 327-368.	1.2	2
124	Interplay of Reverse Transcriptase Inhibitor Therapy and Gag p6 Diversity in HIV Type 1 Subtype G and CRF02_AG. AIDS Research and Human Retroviruses, 2008, 24, 1167-1174.	0.5	6
125	Optimal Cytoplasmic Transport in Viral Infections. PLoS ONE, 2009, 4, e8165.	1.1	15
126	The Role of HIV-1 DNA as an Additional Marker of HIV-1 Infection. Current HIV Research, 2009, 7, 255-265.	0.2	6
127	In search of second-generation HIV integrase inhibitors: targeting integration beyond strand transfer. Future Medicinal Chemistry, 2009, 1, 1259-1274.	1.1	11
128	Reactivation of Latent HIV-1 Infection by the Periodontopathic Bacterium <i>Porphyromonas gingivalis</i> Involves Histone Modification. Journal of Immunology, 2009, 182, 3688-3695.	0.4	117
129	Nef-Induced CD4 Endocytosis in Human Immunodeficiency Virus Type 1 Host Cells: Role of p56 ^{<i>lck</i>} Kinase. Journal of Virology, 2009, 83, 7117-7128.	1.5	25
131	Yeast two-hybrid detection of integrase–host factor interactions. Methods, 2009, 47, 291-297.	1.9	40
132	In vitro anti-HIV activity of five selected South African medicinal plant extracts. Journal of Ethnopharmacology, 2009, 124, 182-188.	2.0	77
133	HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection. Aids, 2010, 24, 2051-2058.	1.0	29
134	Discovery of a Small Molecule Inhibitor of the Interaction Between HIV-1 Proteins and Cellular Cofactors: A Novel Candidate Anti-HIV-1 Drug. Current Chemical Biology, 2010, 4, 188-199.	0.2	0
135	Interaction of human immunodeficiency virus gp120 with the voltageâ€gated potassium channel BEC1. FEBS Letters, 2010, 584, 3513-3518.	1.3	6

ARTICLE

#

#	Article	IF	CITATIONS
136	Inhibition of human immunodeficiency virus type-1 by cdk inhibitors. AIDS Research and Therapy, 2010, 7, 7.	0.7	45
137	HIV-1 Nef membrane association depends on charge, curvature, composition and sequence. Nature Chemical Biology, 2010, 6, 46-53.	3.9	88
138	HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nature Immunology, 2010, 11, 419-426.	7.0	243
139	Novel HIV-1 Knockdown Targets Identified by an Enriched Kinases/Phosphatases shRNA Library Using a Long-Term Iterative Screen in Jurkat T-Cells. PLoS ONE, 2010, 5, e9276.	1.1	31
140	Exogenous Nef Is an Inhibitor of Mycobacterium tuberculosis-induced Tumor Necrosis Factor-α Production and Macrophage Apoptosis. Journal of Biological Chemistry, 2010, 285, 12629-12637.	1.6	32
141	Mucocutaneous manifestations in children with human immunodeficiency virus infection. Indian Journal of Dermatology, Venereology and Leprology, 2010, 76, 458.	0.2	18
142	Role of Abl Kinase and the Wave2 Signaling Complex in HIV-1 Entry at a Post-Hemifusion Step. PLoS Pathogens, 2010, 6, e1000956.	2.1	102
143	Nuclear positional control of HIV transcription in 4D. Nucleus, 2010, 1, 8-11.	0.6	15
144	Transportin 3 and importin $\hat{l}\pm$ are required for effective nuclear import of HIV-1 integrase in virus-infected cells. Nucleus, 2010, 1, 422-431.	0.6	40
146	A structural model of the HIV-1 Rev-integrase complex: The molecular basis of integrase regulation by Rev. Biochemical and Biophysical Research Communications, 2011, 416, 252-257.	1.0	4
147	HIV-1 Infection Induces Acetylation of NPM1 That Facilitates Tat Localization and Enhances Viral Transactivation. Journal of Molecular Biology, 2011, 410, 997-1007.	2.0	27
148	Real-time imaging of the HIV-1 transcription cycle in single living cells. Methods, 2011, 53, 62-67.	1.9	27
149	A Flavonoid, Luteolin, Cripples HIV-1 by Abrogation of Tat Function. PLoS ONE, 2011, 6, e27915.	1.1	60
150	A perspective of the dynamic structure of the nucleus explored at the single-molecule level. Chromosome Research, 2011, 19, 117-129.	1.0	6
151	Highly conserved serine residue 40 in HIV-1 p6 regulates capsid processing and virus core assembly. Retrovirology, 2011, 8, 11.	0.9	22
152	Host Protein Ku70 Binds and Protects HIV-1 Integrase from Proteasomal Degradation and Is Required for HIV Replication. Journal of Biological Chemistry, 2011, 286, 17722-17735.	1.6	66
154	HIV DNA Integration. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006890-a006890.	2.9	254
155	Current understanding in HIV immunopathology and treatment. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 725-728.	0.2	Ο

		CITATION REPORT		
#	Article		IF	CITATIONS
156	Use of ATP analogs to inhibit HIV-1 transcription. Virology, 2012, 432, 219-231.		1.1	23
157	Iron metabolism and the innate immune response to infection. Microbes and Infection,	2012, 14, 207-216.	1.0	214
158	Targets for Inhibition of HIV Replication: Entry, Enzyme Action, Release and Maturation 2012, 55, 84-97.	. Intervirology,	1.2	34
159	Genomic HIV RNA Induces Innate Immune Responses through RIG-I-Dependent Sensing Secondary-Structured RNA. PLoS ONE, 2012, 7, e29291.	çof	1.1	119
160	Selective Histonedeacetylase Inhibitor M344 Intervenes in HIV-1 Latency through Incre Acetylation and Activation of NF-kappaB. PLoS ONE, 2012, 7, e48832.	asing Histone	1.1	35
161	Dynamic Post-Transcriptional Regulation of HIV-1 Gene Expression. Biology, 2012, 1, 1	16-133.	1.3	9
162	The molecular biology of HIV integrase. Future Virology, 2012, 7, 679-686.		0.9	54
163	The immunology of Leishmania/HIV co-infection. Immunologic Research, 2013, 56, 163	-171.	1.3	73
164	Assembling viral channel forming proteins: Vpu from HIVâ€1. Biopolymers, 2013, 99, 5	17-529.	1.2	11
165	Exosome release from infected dendritic cells: A clue for a fast spread of prions in the p Journal of Infection, 2013, 67, 359-368.	eriphery?.	1.7	23
166	HIV-1 pre-mRNA commitment to Rev mediated export through PSF and Matrin 3. Virolo 329-340.	ogy, 2013, 435,	1.1	47
167	Differential Impact of Resistance-Associated Mutations to Protease Inhibitors and Non Reverse Transcriptase Inhibitors on HIV-1 Replication Capacity. AIDS Research and Hun 2013, 29, 1117-1122.		0.5	3
168	Dynamics of the HIV infection under antiretroviral therapy: A cellular automata approa Statistical Mechanics and Its Applications, 2013, 392, 4701-4716.	ch. Physica A:	1.2	27
169	Kinetic uptake profiles of cell penetrating peptides in lymphocytes and monocytes. Bio Biophysica Acta - General Subjects, 2013, 1830, 4554-4563.	chimica Et	1.1	21
170	Innovation spread: lessons from HIV. International Journal for Quality in Health Care, 20)13, 25, 352-356.	0.9	3
171	HIV associated neurocognitive disorders. Gastroenterology Insights, 2013, 5, e8.		0.7	42
172	Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Molecular Therapy - Nucleic Acids, 2013, 2, e137.	Gene Silencing.	2.3	48
173	Molecular Dynamics Simulations Reveal the HIV-1 Vpu Transmembrane Protein to Form Pentamers. PLoS ONE, 2013, 8, e79779.	Stable	1.1	20

#	Article	IF	CITATIONS
174	Prostaglandin E2 Reduces the Release and Infectivity of New Cell-Free Virions and Cell-To-Cell HIV-1 Transfer. PLoS ONE, 2014, 9, e85230.	1.1	15
175	HIV-1 Latency in Monocytes/Macrophages. Viruses, 2014, 6, 1837-1860.	1.5	176
176	Activation of HIV-1 from Latent Infection via Synergy of RUNX1 Inhibitor Ro5-3335 and SAHA. PLoS Pathogens, 2014, 10, e1003997.	2.1	57
177	Correlation of biological activity with computationally derived structural features from transmembrane hetero-dimers of HIV-1 Vpu with host factors. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 1104-1112.	1.4	2
178	CXCR4: A virus's best friend?. Infection, Genetics and Evolution, 2014, 25, 146-156.	1.0	29
179	Host Factors in Retroviral Integration and the Selection of Integration Target Sites. Microbiology Spectrum, 2014, 2, .	1.2	40
180	Attenuating HIV Tat/TAR-mediated protein expression by exploring the side chain length of positively charged residues. Organic and Biomolecular Chemistry, 2015, 13, 11096-11104.	1.5	4
181	<scp>CC</scp> chemokine receptor 5 <i>î"32</i> polymorphism: association analysis and allele distribution among cutaneous leishmaniasis patients from Pakistan. Journal of Cutaneous Pathology, 2016, 43, 564-570.	0.7	6
182	Analysis of HIV-1c-Specific CTL Responses with HIV-1 Reservoir Size and Forms. Viral Immunology, 2016, 29, 184-191.	0.6	5
	27,101171		
184	Amyloidogenic Pattern Prediction of HIV-1 Proteins. , 2017, , 823-895.		1
184 185		0.7	1
	Amyloidogenic Pattern Prediction of HIV-1 Proteins. , 2017, , 823-895. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: A combinatorial approach. Biochemistry	0.7	
185	Amyloidogenic Pattern Prediction of HIV-1 Proteins. , 2017, , 823-895. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: A combinatorial approach. Biochemistry (Moscow), 2017, 82, 1716-1743.		3
185 186	 Amyloidogenic Pattern Prediction of HIV-1 Proteins. , 2017, , 823-895. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: A combinatorial approach. Biochemistry (Moscow), 2017, 82, 1716-1743. DDX3 in HIV-1 infection and sensing: A paradox. Cytokine and Growth Factor Reviews, 2018, 40, 32-39. Harnessing nanostructured systems for improved treatment and prevention of HIV disease. 	3.2	3 28
185 186 187	Amyloidogenic Pattern Prediction of HIV-1 Proteins. , 2017, , 823-895. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: A combinatorial approach. Biochemistry (Moscow), 2017, 82, 1716-1743. DDX3 in HIV-1 infection and sensing: A paradox. Cytokine and Growth Factor Reviews, 2018, 40, 32-39. Harnessing nanostructured systems for improved treatment and prevention of HIV disease. Bioengineering and Translational Medicine, 2018, 3, 102-123. Spontaneous reactivation of latent HIV-1 promoters is linked to the cell cycle as revealed by a	3.2 3.9	3 28 18
185 186 187 188	Amyloidogenic Pattern Prediction of HIV-1 Proteins. , 2017, , 823-895. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: A combinatorial approach. Biochemistry (Moscow), 2017, 82, 1716-1743. DDX3 in HIV-1 infection and sensing: A paradox. Cytokine and Growth Factor Reviews, 2018, 40, 32-39. Harnessing nanostructured systems for improved treatment and prevention of HIV disease. Bioengineering and Translational Medicine, 2018, 3, 102-123. Spontaneous reactivation of latent HIV-1 promoters is linked to the cell cycle as revealed by a genetic-insulators-containing dual-fluorescence HIV-1-based vector. Scientific Reports, 2018, 8, 10204.	3.2 3.9 1.6	3 28 18 8
185 186 187 188 189	Amyloidogenic Pattern Prediction of HIV-1 Proteins. , 2017, , 823-895. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: A combinatorial approach. Biochemistry (Moscow), 2017, 82, 1716-1743. DDX3 in HIV-1 infection and sensing: A paradox. Cytokine and Growth Factor Reviews, 2018, 40, 32-39. Harnessing nanostructured systems for improved treatment and prevention of HIV disease. Bioengineering and Translational Medicine, 2018, 3, 102-123. Spontaneous reactivation of latent HIV-1 promoters is linked to the cell cycle as revealed by a genetic-insulators-containing dual-fluorescence HIV-1-based vector. Scientific Reports, 2018, 8, 10204. The Diverse Roles of microRNAs at the Host–Virus Interface. Viruses, 2018, 10, 440. The Role of Macrophages in HIV-1 Persistence and Pathogenesis. Frontiers in Microbiology, 2019, 10,	3.2 3.9 1.6 1.5	3 28 18 8 87

#	Article	IF	Citations
193	The Replication Strategy of Foamy Viruses. Current Topics in Microbiology and Immunology, 2003, 277, 1-26.	0.7	67
194	CONGENITAL AND ACQUIRED IMMUNODEFICIENCIES. , 2010, , 463-488.		3
195	Diseases of the Immune System. , 2010, , 183-257.		5
196	Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. Aids, 2003, 17, 1613-20.	1.0	22
197	Host Factors in Retroviral Integration and the Selection of Integration Target Sites. , 0, , 1035-1050.		2
198	Optimized Infectivity of the Cell-Free Single-Cycle Human Immunodeficiency Viruses Type 1 (HIV-1) and Its Restriction by Host Cells. PLoS ONE, 2013, 8, e67170.	1.1	18
199	Cellular Reservoirs of HIV-1 and their Role in Viral Persistence. Current HIV Research, 2008, 6, 388-400.	0.2	283
200	Design, Synthesis, Molecular Modeling and Anti-HIV Assay of Novel Quinazolinone Incorporated Coumarin Derivatives. Current HIV Research, 2020, 18, 41-51.	0.2	13
201	Infectious and Non-infectious Etiologies of Cardiovascular Disease in Human Immunodeficiency Virus Infection. Open AIDS Journal, 2016, 10, 113-126.	0.1	1
202	C-Type Lectin-HIV Attachment on Dendritic Cells: Innate Immune Recognition and Processing or Mediators of HIV Transmission?. Trends in Glycoscience and Glycotechnology, 2002, 14, 255-271.	0.0	6
203	From Roscovitine to CYC202 to Seliciclib – from bench to bedside: discovery and development. BioDiscovery, 2013, , .	0.1	7
204	VIH/sida. , 2007, , 351-367.		0
205	HIV-Infektion und AIDS. , 2007, , 645-650.		0
207	Acquired Immune Deficiency Syndrome. , 2008, , 171-201.		0
208	Human Immunodeficiency Virus Infection and the Acquired Immunodeficiency Syndrome. , 2010, , 240-255.		0
209	Infections of the Nervous System. , 2010, , 933-944.		1
210	Retroviruses and retroviral infections. , 2010, , 1609-1616.		0
211	Infections of the Nervous System. , 2012, , 1211-1230.		0

#	Article	IF	Citations
213	Memory Phenotypes of HIV-Specific CD8+ T Cell Responses Are Independent of Functional Activity as Defined by Cytokine Output. Open Journal of Immunology, 2014, 04, 83-95.	0.5	0
215	Immunology and AIDS. , 0, , 529-551.		0
216	Acquired Immune Deficiency Syndrome. , 2016, , 293-330.		0
217	HIV-1 Dynamics in the Host Cell: A Review of Viral- and Host- Protein Interactions and Potential Therapeutic Targets for HIV-1 Infection. The Einstein Journal of Biology and Medicine: EJBM, 2016, 22, 10.	0.2	0
218	Diseases of the Immune System. , 0, , 112-112.		2
222	The HIV-1 passage from cytoplasm to nucleus: the process involving a complex exchange between the components of HIV-1 and cellular machinery to access nucleus and successful integration. International Journal of Biochemistry and Molecular Biology, 2012, 3, 70-85.	0.1	26
223	Natural antimicrobial peptides as promising anti-HIV candidates. Current Topics in Peptide and Protein Research, 2012, 13, 93-110.	1.0	21
224	Progress in HIV-1 Integrase Inhibitors: A Review of their Chemical Structure Diversity. Iranian Journal of Pharmaceutical Research, 2016, 15, 595-628.	0.3	35
225	Crosstalk between R848 and abortive HIVâ€1 RNAâ€induced signaling enhances antiviral immunity. Journal of Leukocyte Biology, 2022, , .	1.5	4
226	Importin KPNA2 confers HIV-1 pre-integration complex nuclear import by interacting with the capsid protein. Antiviral Research, 2022, 200, 105289.	1.9	6
227	ALV-miRNA-p19-01 Promotes Viral Replication via Targeting Dual Specificity Phosphatase 6. Viruses, 2022, 14, 805.	1.5	2
233	Microbiota-derived short chain fatty acids: Their role and mechanisms in viral infections. Biomedicine and Pharmacotherapy, 2023, 160, 114414.	2.5	5
234	Specialized DNA Structures Act as Genomic Beacons for Integration by Evolutionarily Diverse Retroviruses. Viruses, 2023, 15, 465.	1.5	1